ÂÜÀòÂÒÂ×

Shaohua Xu has worked in the field of CAR-T Immunotherapy since 2006. From 2006 to 2011, they were a Ph.D. student in Biochemistry and Molecular Biology at Peking Union Medical College and National Institute of Biological Sciences. During this time, they identified a critical transcriptional factor that regulates Salicic acid biosynthesis, set up a high-throughput screening system, and discovered novel genetic components involved in host-pathogen interaction. From 2011 to 2012, they were a Postdoctoral Fellow at the National Institutes of Biological Sciences in Beijing. In 2012, they became a Postdoctoral Fellow at the Gladstone Institutes and UCSF. Since 2017, they have been a Principal Scientist, Senior Scientist, and Scientist at Eureka Therapeutics, Inc.

Shaohua Xu obtained a Doctor of Philosophy (Ph.D.) in biochemistry and molecular biology from Peking Union Medical College in 2011. Prior to this, they earned a Bachelor's Degree in Biological Science from Peking University in 2006.